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Background: The generation of anti-adenovirus neutralizing antibody (NAb) in humans 
severely restricts the utilization of recombinant adenovirus serotype 5 (Ad5) vectors in gene 
therapy for a wide range of clinical trials. To overcome this limitation, we ionically complexed 
Ad5 with a newly synthesized copolymer, which we called APC, making an adenovirus shielded 
from NAb.
Methods: APC, a cationic polyethylene glycol derivative, was synthesized via two steps of 
ring-opening copolymerization of ethylene oxide and allyl glycidyl ether, followed by the addi-
tion of 2-mercaptoethylamine. The copolymer or the control PEI-2k was ionically complexed to 
anionic Ad5 in 5% glucose, and in vitro transduction assays were carried out in coxsackievirus 
and adenovirus receptor-positive cells (A549) and coxsackievirus and adenovirus receptor-
negative cells (B16 and SKOV3). The physical properties and morphology of adenovirus 
alone or the complexes were investigated respectively by zeta potential, size distribution, and 
transmission electron microscopy image. Then cytotoxicity of APC was examined using 3-[4, 
5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide assays. Finally, the ability of APC to 
protect adenovirus from NAb was evaluated by transfection assays after a neutralizing effect.
Results: APC was successfully synthesized and showed a low cytotoxicity. Positively 
charged Ad5/APC exhibited slightly increased diameter (130.2 ± 0.60 nm) than naked Ad5 
(115.6 ± 5.46 nm) while Ad5/PEI-2k showed severe aggregation (1382 ± 79.9 nm). Ad5/APC 
achieved a gene transfection level as high as Ad5/PEI-2k in A549 or B16 cells, and significantly 
higher than Ad5/PEI-2k in SKOV3 cells. Most importantly, after the exposure to the neutral-
izing antibody, naked Ad5 and Ad5/PEI-2k exhibited poor gene expression while Ad5/APC 
still showed significantly efficient gene expression.
Conclusion: Our results demonstrated that Ad5/APC complex offered good protection for Ad5 
against NAb in vitro and suggested a potential strategy of resistance to NAb in vivo.
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Introduction
Recombinant adenovirus vectors (Adv) have been under extensive exploration as gene 
delivery systems for gene therapy or vaccines.1–3 As reported in 2009, viral vectors for 
gene therapy accounted for 66% of all those in clinical trials, approximately 25% of 
which were Adv-based vectors.4 In particular, adenovirus-mediated p53 gene therapy 
has been proven effective in clinical trials by intratumoral administration for cancer 
treatment.5,6 Recently, Adv-based research has entered the new fields of nanomedi-
cine and nanodiagnostics.7 The broad application based on Adv originated from their 
special advantages over other viral and nonviral vectors, primarily containing their 
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high efficiency in transduction and transgenic expression 
and low pathogenicity.
Unfortunately, capsid proteins of Adv are immunogenic; 
in animal and human studies anti-adenovirus neutralizing 
antibodies (NAbs) were elicited within one week after initial 
exposure to Adv.8,9 The titer of NAb increased to a peak 
within 4 weeks.10 When readministrated, NAb recognized 
and neutralized Adv before internalizing into targeted cells, 
leading to an inefficient transduction. Moreover, pre-existing 
anti-Adv neutralizing antibodies in a large population of 
people worldwide, especially anti-Ad5 antibodies, is a barrier 
for Adv-mediated clinical applications.11–13 In addition, Adv 
are limited to local administration due to substantial liver 
tropism and subsequent severe hepatotoxicity after systemic 
administration.14 Therefore, none of the Adv-mediated gene 
therapy drugs has been FDA-approved so far.
Over the past decade, the most frequently used strategies 
to solve this problem have been hybrid vectors that combine 
viral and nonviral vectors. Nonviral vectors are nonimmuno-
genic, thus a liposome envelope or a polymer coating shields 
Adv and thereby reduces the immunogenicity or prevents 
recognition by the immune system or NAb. Adv can be 
divided into two groups: those that are covalently chemically 
conjugated and those that are physically self-assembled, each 
of which has their drawbacks. A typical example of chemi-
cal conjugation is pegylation, which has been confirmed 
as an efficient technique in several studies.15–19 However, 
studies have shown that chemical conjugation reduced infec-
tion activity of Adv, associated with steric hindrance from 
flexible polyethylene glycol (PEG) chains, resulting in a 
decreased gene transduction and transgenic expression.16,20,21 
This can be partially compensated for by a targeted ligand 
covalently conjugated to the PEG (ligand-PEG-Adv).22,23 
Moreover, chemical conjugation showed protection of Adv 
in a titer-related way, but still failed in complete avoidance 
of the immune response or a negligible influence by NAb. 
The techniques of pegylation need to be further optimized, 
including the covalent site on Adv, PEG size and density, 
and reaction conditions.15,21,24,25 Alternatively, Adv can 
be modified by physical self-assembly, which is easier to 
handle and avoids potential inactivity of Adv during chemi-
cal synthesis. Cationic polymers (polyethylenimine [PEI], 
lipofectamine, and chitosan) have been widely investigated 
in enhancing gene transduction abilities, but most of the 
complexes showed weak evasion from NAb.26–30 Moreover, 
aggregation of Adv induced by cationic polymers suggested 
unstable complexation29 and simultaneous toxicity associated 
with cationic polymers also limited clinical applications.31 
For the efficient delivery of plasmid DNA, it has been reported 
that PEG covalently conjugated to cationic polymers such as 
PEG-poly-L-lysine (PLL),32 PEG-PEI,33 and PEG-chitosan34 
could form stable and low toxic nonviral vectors. Therefore, 
we hypothesized that a PEG grafted cationic polymer can 
improve the stability of Adv-cationic polymer complexes and 
that linear PEG extending outside can protect Ad5 from NAb 
as well as achieve effective transgenic expression.
In our study, cationic PEG derivatives (APC), a linear 
PEG with one side blocked by amine pendants, was synthe-
sized to immobilize onto negatively charged capsid proteins 
of Ad5 for evading NAb (Figure 1). We hypothesized that 
amines play a bridge-like effect, linking a linear PEG and 
Ad5. Simultaneously, the linear PEG extends outside, pro-
tecting Ad5 from interaction with NAb or cells in blood. 
Then replicate-incompetent Ad5 expressing β-gal (Ad5-
LacZ) were complexed with APC or the control PEI-2k in 
a serial ratio. Next, in vitro transfection assays were carried 
out in coxsackievirus and adenovirus receptor (CAR)-
positive cells (A54935) and CAR-negative cells (B16,36 
SKOV337). Finally, the ability of APC to protect Ad5 from 
evading NAb was evaluated by in vitro neutralizing assays 
in A549 cells.
Materials and methods
Chemical reagents and biomaterials
Branched PEI (2 kd), allyl glycidyl ether (AGE), and 3-[4, 
5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bro-
mide (MTT) were purchased from Sigma Chemical Co, 
(St Louis, MO). 2-mercaptoethylamine was obtained from 
Aladdin Chemistry Co, Ltd, (Shanghai, China). Ethylene 
oxide (EO) was obtained from Xinhua Institute of Active 
Material (Changzhou, Jiangsu, China). O-nitrohenyl-β-D-
galactopyranoside and cesium chloride (molecular biology 
grade) were obtained from Amersco (Solon, OH).
Cell lines
E1-transformed human embryonic kidney cell line HEK 
293 was purchased from ATCC (CRL1573) and cultured in 
Dulbecco’s modified Eagle’s medium (GIBCO-BRL, Grand 
Island, NY) supplemented with 10% fetal bovine serum 
(FBS), 100 units/mL penicillin, and 100 µg/mL streptomycin, 
incubated at 37°C in a 95% humidified atmosphere contain-
ing 5% CO2. Non-small cell lung carcinoma cell line A549, 
murine melanoma cell line B16, and human ovarian cancer 
cell line SKOV3 were obtained from Chinese Academy of 
Sciences (Shanghai, China) and cultured in RPMI-1640 
(GIBCO-BRL, Grand Island, NY) complemented with 10% 
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FBS, 100 units/mL penicillin, and 100 µg/mL streptomycin, 
cultured in the same conditions as above.
Adenovirus preparation
E1/E3-deleted recombinant type 5 adenovirus vectors encod-
ing LacZ reporter gene and expressing β-galactosidase   
(Ad5-LacZ) were purchased from the Vector Gene Technol-
ogy Company Limited (Beijing, China). Replication-deficient 
Ad5 vectors were amplified in HEK 293 cells and purified 
from the cells’ lysate through two steps of CsCl gradients 
ultracentrifugation. Next, the underlayer of viral band was 
desalted by dialysis at 4°C for 4 hours against dialysis buf-
fer (10 mM Tris pH 8.0, 2 mM MgCl2, 5% sucrose) with a 
cellulose ester membrane of molecular weight (MW) cut 
off 25 kd before being stored in aliquots at −80°C until use. 
Finally, the titer of virus stock was evaluated as 2.5 × 1011 
plaque-forming units per mL (pfu/mL) by established plaque-
forming assay or 2.0 × 1012 viral particles per mL (vps/mL) by 
measurements of ultraviolet absorption at 260 nm (OD260). 
Multiplicity of infection (MOI) value is defined as the ratio 
of total number of pfu per number of cells. In our in vitro 
study, MOI was approximately equivalent to 40.
Synthesis of the copolymer (APC)
Protection of 2-aminoethanol with tert-
butoxycarbonyl (Boc) group
Boc group was conjugated to 2-amino ethanol to pre-
vent amine from oxidation in the following process. 
Typically, a solution of sodium hydroxide (10.03 g) in 50 mL 
distilled water was added to a solution of β-aminoethanol 
(7.37 g) in 25 mL methanol. While stirring in an ice bath, 
(Boc)2O (32.72 g) in 25 mL methanol was added dropwise 
to the mixture. After another 24 hours stirring at room 
  temperature, the reaction mixture was filtrated and the filtrate 
was extracted three times by acetoacetate, and then washed 
with distilled water until it became neutral, followed by wash 
again with saturated salt solution. Next, the mixture was dried 
by waterless sodium sulfate, and the solvent was removed by 
rotary evaporation under reduced pressure. Finally a viscous 
product was obtained, namely Boc-aminoethanol.
Boc-(EO)n/(AGE)m copolymerization
Boc-(EO)n/(AGE)m was copolymerized by two steps of ring-
opening of EO firstly and AGE. Typically, Boc-aminoethanol 
(0.88 g) as the initiator, after dehydration for 1 hour at 90°C 
through oil pump reduced pressure, was dissolved in nonaque-
ous dioxane. While stirring at 60°C, sodium cyanide (60%, 
0.92 g) was added, and nonaqueous EO (100 mL) purified by 
reforming was added dropwise to the mixture by a constant 
pressure funnel connected with a condensing tube (4°C−8°C 
recirculation water) and a drying tube filled with waterless 
calcium chloride to maintain an anhydrous reaction system. 
After EO recirculation came to an end, AGE (30.1 g) was 
added to the reaction mixture and stirred for another 2 days 
at 60°C. Afterwards, water was added to stop the reaction, 
and 1 M hydrochloric acid was used to adjust pH to neutral. 
Neutralizing antibody evasion
Antibody
amino-(EO)n-(AGE)m-Cys(APC)
Figure 1 Schematic representation of adenovirus complexed with cationic PEG derivative (Ad5/APC) for evading anti-adenovirus neutralizing antibody (NAb).
Abbreviations: EO, ethylene oxide; AGE, allyl glycidyl ether; APC, cationic PEG derivative; Ad5, adenovirus vectors type 5.
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The solvent was then removed by rotary evaporation under 
reduced pressure, and the residue was again dissolved in 
dichloromethane, dried by waterless sodium sulfate, filtrated, 
centrifuged, and the supernatant was condensed by rotary 
evaporation under reduced pressure. Finally, after further 
purification by repeated precipitation of diethyl ether three 
times, a yellowish product resulted, namely Boc-(EO)n/(AGE)
m, where n or m is represented as the number of monomers.
Deprotection of Boc-(EO)n/(AGE)m
Boc-(EO)n/(AGE)m was deprotected by trifluoroacetic acid. 
Briefly, Boc-(EO)n/(AGE)m (2.0 g) copolymer was dissolved 
in 10 mL dichloromethane containing 40% trifluoroacetic 
acid (v/v), which was stirred at RT for 2 hours. After removal 
of the solvent by rotary evaporation under reduced pressure, 
the mixture was redissolved in methanol and dialyzed for 
2 days against distilled water through cellulose (3.5 kd). 
Finally, lyophilization of the solution gave a product, namely 
amino-(EO)n/(AGE)m.
Addition of 2-aminoethanethiol to amino-(EO)n/
(AGE)m-CYS (APC)
Addition of 2-aminoethanethiol to the double bond of amino-
(EO)n/(AGE)m was performed according to the protocol 
reported by Koyama et al.38 Briefly, amino-(EO)n/ (AGE)m 
(1.03 g) was dissolved in methanol (4 mL), and was added 
dropwise to the solution of 2-aminoethanethiol hydrochloride 
(3.01 g) in methanol (8 mL). After stirring at room tempera-
ture for 2 days, the reaction mixture was evaporated to remove 
the methanol. The residual syrup was dialyzed against distilled 
water for 3 days though cellulose membrane (MW cut off 3.5 
kd). Lyophilization of the solution gave a yellowish product, 
namely amino-(EO)n/(AGE)m- Cys (APC).
Characterization of APC
To confirm synthesis of the APC polymer, the 1H-NMR 
spectras of intermediates and the final product APC were 
recorded on liquid samples (CD3CL or D2O; Sigma-Aldrich) 
in a Varian UNITY INOVA400 NMR Spectrometer (Palo 
Alto, CA) at 400 MHz.
The MW of APC was estimated by gel permeation 
chromatography (GPC), calibrated with PEG using   Shodex 
KB-803 column (Shoko Co, Tokyo, Japan), Waters 515 
pump, and Waters 2410   Refractive Index Detector  (Waters 
Corporation, Milford, MA). Briefly, APC was dissolved in 
ultrapure water at a concentration of 10 mg/mL. Acetate buf-
fer 0.5 M (acetate-sodium acetate) was used as eluent with 
a flow rate of 0.5 mL/min.
To determine the content of amines per molar of APC or 
indirectly charge APC bearing, analysis of nitrogen, carbon, 
and hydrogen was performed using an elementary analysis 
instrument (CARLO ERBA 1106; Carlo, Milan, Italy) and the 
sulfur atom was measured using the oxygen flask combustion 
method. The sample was in a completely dry form.
Preparation of Ad5 complexed cationic 
polymer
Complexes of Ad5 and APC or PEI-2k were formed as 
follows. Initially, stock solutions of APC (10 mg/mL), 
PEI-2k (10 mg/mL) and 5% glucose (w/v) in ultrapure 
water were respectively filtered through 0.22 µm pore 
sized filters. Then a serial concentration of dilutions of 
APC and PEI-2k in 5% glucose were respectively added 
dropwise to the isovolumic Ad5-LacZ dilution in 5% 
glucose with fixed particles of Ad5. After gently pipetting 
several times, the samples were incubated at room tem-
perature for 25∼30 min to form complexes of Ad5/APC 
or Ad5/PEI-2k. Complexes were freshly prepared before 
use every time.
In vitro transfection assays
To determine the best ratio of naked Ad5 and polymers 
(APC or PEI-2k), in vitro transfection assays were carried 
out in CAR over-expressing A549 cells. Briefly, A549 cells 
were seeded in 24 wells tissue culture plate at a density of 
1 × 105 cells per well for 24 hours. When the cells reached 
80%∼90% confluence, Ad5/LacZ (1.25 × 107 pfu per well, 
1 × 108 vps per well, MOI 40) were complexed with a serial 
dose of APC and PEI-2k (50, 150, 300, 450, 600, 750, 
1000 ng) in 5% glucose. After staying at room temperature 
for 25∼30 min, 50 µL per well of complexes were applied to 
the cells in 200 µL RPMI-1640 medium without serum. After 
incubation at 37°C for 4 hours, the medium was replaced by 
fresh RPMI-1640 complete medium. After 24 hours incuba-
tion, cells were washed by PBS and lyzed by cell lysis buffer. 
Next, β-galactosidae and total protein concentration were 
respectively quantified by colorimetry using o-nitrohenyl-β-
D-galactopyranoside as the substrate and a BCA kit (Pierce, 
Rockford, IL). The transfection efficiency was represented 
as unit of β-galactosidase per milligram of total protein   
(u/mg protein).
After the optimal ratio of Ad5 and polymers were 
determined, in vitro transfection assays of naked Ad5 or 
complexes at the optimal ratio were also carried out in CAR 
negative cells (SKOV3 and B16) with the same processes as 
described above.
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Cytotoxicity
For cytotoxicity assays, A549, SKOV3, and B16 cells 
were seeded in 96 wells tissue culture plate (1 × 104 cells/
well) in RPMI-1640 complete medium. The background 
wells had no cells but RPMI-1640 complete medium. 
When cells achieved 80%∼90% confluence, 10 µL per well 
of freshly prepared complexes of Ad5 (2 × 107 vps/well, 
2.5 × 106 pfu/well), coated with a serial concentration of 
APC or PEI-2k dilutions respectively in 5% glucose were 
treated to the cells in 90 µL RPMI-1640 medium without 
serum, with the final concentrations of copolymers as follows: 
1, 5, 10, 20 µg/mL. The control and background wells were 
added to 10 µL of 5% glucose in 90 µL RPMI-1640 medium 
without serum. Each sample had five repeated wells. After 
maintaining for 4 hours, the medium were replaced by 200 
µL of fresh RPMI-1640 medium containing 10% FBS for a 
further 24 hours incubation, 20 µL per well of MTT solution 
(5 mg/mL) was added to the plate and further maintained for 
4 hours at 37°C. Subsequently, the medium and MTT were 
carefully removed and replaced by 150 µL dimethyl sulfoxide. 
After shaking at 37°C for 30 min, the absorbance of each plate 
was read at 490 nm using varioskan@Flash instrument (Thermo 
Scientific, Waltham, MA). Relative cell viability was calculated 
by the formula as (Asample−Ablank)/(Acontrol−A blank) × 100%.
Size and zeta potential measurement  
of naked adenovirus and complexes
The average diameter and zeta potential of naked Ad5 and 
complexes of Ad5/APC and Ad5/PEI-2k at the optimal ratio 
were respectively measured by dynamic light scattering and 
electrophoretic light scattering, using a photon correlation 
spectroscopy (Malvern Zetasizer Nano ZS90, Malvern 
  Instruments Ltd, Worcestershire, UK) with a 50 mV laser. 
Before measurement, 200 µL of naked Ad5 or freshly prepared 
complexed samples of Ad5/PEI-2k, Ad5/APC containing 
2 × 1010 vps of Ad5-LacZ were diluted to 1 mL with ultrapure 
water. Then the measurement was performed at 25°C and a 
fixed angle of 90 with 2 min of equilibrium time and auto-
matic cycles of measurement determined by the instrument. 
Each measurement was carried out in triplicate.
Morphological investigation by transmission 
electron microscopy (TEM)
The morphology of Ad5 alone or complexes of Ad5/APC 
were observed with a transmission electron microscope 
(tecnaiG2F-20, FEI, Eindhoven, Holland) at an accelerating 
voltage of 20 kV , using a negative stain technique. Briefly, 20 
µL of naked Ad5 or freshly prepared complex (Ad5/APC) at 
optimal ratio containing 1 × 109 vps of Ad5 were respectively 
added on a copper grid and left for 10 min, enabling a suf-
ficient adsorption. Then the solution was removed with filter 
paper and replaced with 1% aqueous uranyl acetate, stain-
ing for 1 min. After removal of the dye with filter paper and 
dryness at 37°C, the samples were imaged by transmission 
electron microscopy.
Evaluation of APC protecting Ad5  
from NAb
Primarily for preparation of antiserum from mice, C57BL/6 N 
mice (4 to 5 week old, male) were obtained from the 
  Laboratory Animal Center of Sichuan University, and were 
housed under specific pathogen-free conditions for one week 
to acclimate. The animal experiments were approved by the 
Institutional Animal Care and Ethic Committee of Sichuan 
University. On day −28, the mice were randomly divided 
into two groups – one group of mice was immunized by 
intramuscular injection in the right hind limb with 5 × 1010 
vps of recombinant adenovirus (Ad5-LacZ) in 50 µL of 5% 
glucose per mouse, and the other group was intramuscularly 
administered 5% glucose. On day −14, this immunization was 
repeated. On day 0, the blood was respectively collected from 
the orbits vein of the immunized and nonimmunized mice. 
The blood was coagulated at room temperature for 15 min 
and centrifuged (2000 rpm, 30 min). Finally, the superna-
tant antiserum and blank serum was respectively collected, 
pooled, and stored at −80°C before use.
In order to evaluate the ability of APC to protect Ad5 
evading from NAb, the antiserum or blank serum was com-
plement inactivated at 56°C for 30 min in advance. Naked 
Ad5 (50 µL), and complexes of Ad5/PEI-2k or Ad5/APC at 
the optimal ratio containing 1.25 × 107 pfu of Ad5-LacZ, were 
respectively incubated with 200 µL of diluted antiserum or 
blank serum at 37°C for 1 hour, making a neutralizing effect 
and the final dilution of the serum was 1:50 and 1:250. Then 
250 µL per well of the mixture was respectively treated to 
A549 cells in 24 wells tissue culture plate, for which a con-
fluence of 80%∼90% had been achieved. The following pro-
cesses were the same as the in vitro transfection.   According 
to comparison of gene expression efficiency among naked 
Ad5, complexes of Ad5/PEI-2k and Ad5/APC in A549 at 
the presence of antiserum or blank serum, the ability of APC 
protecting Ad5 evading NAb were relatively evaluated.
Statistical analysis
All the above assays were performed at least in triplicate. 
The data are shown as the mean ± standard deviation (SD). 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
989
Adenovirus complexed with PEG derivative for evading NAbInternational Journal of Nanomedicine 2012:7
Statistical analysis was carried out by Student’s t-test. The value 
of P , 0.05 was considered to be statistically significant.
Results
Synthesis and characterization of APC
APC was prepared by two steps of ring-opening copolymer-
ization of EO and AGE, with Boc-aminoethanol as the initia-
tor, followed by deportation of the Boc group and addition 
of 2-mercaptamine to the pendant of allyl groups. The main 
routes of synthesis are given in Figure 2. The synthesis of 
APC was confirmed by 1H-NMR as follows.
Firstly, on the spectra of Boc-aminoethanol, occurrence of 
peaks of δ (CH3CO–) = 1.448, δ (–CH2OH) = 3.285 indicated 
that Boc group had been successfully congjugated to the 
amine of aminoethanol. Then the polymerization of EO with 
Boc-aminoethanol as an initiator has been characterized by 
the typical peaks of δ (–O–CH2–CH2–O) = 3.740∼3.382 
and δ (–O–CH–CH2–) = 3.803. The following polymer-
ization of AGE was confirmed by the double bond peak of 
δ (–CH = CH2–) = 5.867 and δ (–CH = CH2–) = 5.216. (The 
chemical shift of hydrogen atoms is shown in bold in this 
paragraph.) Next, deprotection of Boc group was achieved 
due to disappearance of the methyl peak of Boc group, and the 
spectra of final product, Amino-(EO)n/(AGE)m-Cys, showed 
no alkenyl peaks, demonstrating a complete addition.
The MW of APC was estimated to be 19571 Da by GPC 
with PEG as standard substance. Elemental analysis of APC 
showed that nitrogen took up 2.38%, carbon 48.76%, hydro-
gen 8.21%, and sulfur 4.88%. From the mass percentage of 
nitrogen and carbon together with the MW and molecular 
formula of APC, it can be calculated that n was 36 and 
m was 288, respectively, indicating the number of monomers 
of EO and AGE. In the following, the linear PEG on APC was 
inferred to 12.6 kd with 36 amines per molecular APC.
Enhanced transgenic expression efficiency 
by adenovirus complexed with APC
To evaluate the optimal ratio of polymer (APC, PEI-2k) 
and Ad5-LacZ, Ad5-LacZ (1.25 × 107 pfu) coated with a 
serial dose of PEI-2k or APC over the range from 50 ng 
to 1000 ng were transfected in CAR-rich A549 cells. As 
shown in Figure 3A, the peaks of the two curves, indicat-
ing the relation of gene transfection efficiency and polymer 
weight, revealed the optimal proportion of adenovirus and 
polymers (APC, PEI-2k), 1.25 × 107 pfu of adenovirus-
LacZ corresponded to 600 ng for both PEI-2k and APC 
(P , 0.05). Excitingly, APC-mediate Ad5 gene transfec-
tion at the optimal ratio achieved as efficiently as PEI-2k 
(P . 0.05). Both of the polymers enhanced gene expres-
sion of naked Ad5 by approximately 10 times. The results 
may suggest a CAR-independent transfection for polymer 
shielded adenovirus.
In the following, in order to confirm superior gene trans-
fection efficiency of APC and PEI-2k in a CAR-ablate way, 
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Figure 2 Synthesis scheme of APC. (a) (Boc)2O, NaOH, MeOH:H2O = 1:1 (v/v), RT, 12 hours. (b) NaH, EO, dioxane, 60°C, 4 days. (c) NaH, AGE, 60°C, 3 days. 
(d) Trifluoroacetic acid:dichloromethane = 1:4 (v/v), RT, 2 hours. (e) MeOH, RT, 2 days.
Abbreviations: APC, cationic PEG derivative; EO, ethylene oxide; AGE, allyl glycidyl ether; RT, room temperature.
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in vitro transfection assays of the complexes at the optimal 
ratio were performed as above in CAR-negative SKOV3 and 
B16 cells. As represented in Figure 3B, naked Ad5 showed 
far lower expression of β-gal in B16 cells and SKOV3 cells 
than in A549 cells. Greatly increased expression of β-gal was 
observed for Ad5 complexed with APC or PEI-2k. The gene 
expression efficiency of Ad5 was improved about 40 times in 
B16 cells and about 23 times in SKOV3 cells by the com-
plexation with APC. Interestingly, there was no significant 
difference between APC and PEI-2k for Ad5-mediated gene 
therapy in A549 or B16 cells. While in SKOV3 cells, APC 
exhibited significantly higher gene expression than PEI-2k 
(P , 0.001). The results further confirmed that Ad5 with cat-
ionic polymers modification enabled improved gene expres-
sion in CAR-positive or negative cells. As expected, APC can 
achieve as efficient transduction as commercial PEI-2k.
Investigation of physical properties and 
morphology of Ad5 alone or complexes
Particle sizes and surface potential of naked adenovirus or 
complexes (Ad5/PEI-2k, Ad5/APC) at the optimal ratio were 
measured by dynamic light scattering and electrophoretic light 
scattering respectively. As shown in Table 1, the surface poten-
tial of the complexes turned positive, 9.64 ± 0.67 mV for Ad5/
PEI-2k and 31.23 ± 0.40 mV for Ad5/APC while naked Ad5 
remained negatively charged, −17.56 ± 0.53 mV . This result sug-
gested that the copolymers had been ionically anchored on the 
viral surface, forming newly cationic hybrid vectors. Compared 
with naked Ad5 (115.6 ± 5.46 nm), Ad5/APC (130.2 ± 0.60 nm) 
had a slightly increased particle diameter. But the particle diam-
eter of Ad5/PEI-2k was over 1 micrometer (1382 ± 79.9 nm) 
suggesting a severe aggregation induced by PEI-2k. Low poly-
dispersity index value indicated all formulations had uniform 
distribution. The study demonstrated that APC and PEI-2k were 
accessible to complex with adenovirus by ionic interaction. 
Moreover, APC modification makes adenovirus relatively stable 
to commercial PEI-2k, which may facilitate gene delivery in 
vivo. Figure 4 showed the morphology of naked Ad5 or APC-
coated Ad5 complex at an optimal ratio by TEM. Both naked 
Ad5 and Ad5/APC complex showed regular morphology with 
uniform distribution. But compared to Ad5 alone, Ad5/APC 
complex exhibited a notable shell-core structure. This result 
indicated that APC polymer had been ionically anchored onto 
the surface protein of Ad5, forming a coated Ad5.
Cytotoxicity
Cytotoxicity of adenovirus coated with a serial concentra-
tion of APC, PEI-2k, or PEI-25k (1, 5, 10, 20 µg/mL) were 
determined on A549, SKOV3, and B16 cells, using MTT 
Table 1 Zeta potential and size distribution of naked Ad5 and 
complexesa
Zeta potential 
(mV)
Size (nm) PDI
Naked Ad5 −17.56 ± 0.53 115.6 ± 5.46 0.04 ± 0.037
Ad5/PEI-2k 9.64 ± 0.67 1382 ± 79.9 0.084 ± 0.11
Ad5/APC 31.23 ± 0.4 130.2 ± 0.60 0.02 ± 0.01
Notes:  aComplexes  were  respectively  prepared  at  optimal  ratio.  Values  are 
represent as mean ± SD, n = 3.
Abbreviations:  Ad5,  adenovirus  vectors  type  5;  PDI,  polydispersity  index; 
PEI, polyethylenimine; APC, cationic PEG derivative; Ad5/APC, adenovirus complexed 
with APC; Ad5/PEI-2k, adenovirus complexed with PEI-2k; SD, standard deviation.
Figure 3 In vitro transfection assays of Ad5 or complexes. To determine the best 
ratio of Ad5 and polymers, transfection assays were performed in A549 cells treated 
with Ad5-LacZ (1.25 × 107 pfu/well) complexed with a serial dose of polymers, PEI-2k 
or APC (50∼1000 ng). following incubation for 24 hours after transfection, the cells 
was lyzed for quantity of β-galactosidae (A). Transfection assays in A549, B16, and 
SKOV3 treated with Ad5 alone (1.25 × 107 pfu/well) or complexes (Ad5/PEI-2k or 
Ad5/APC) at the optimal ratio (B).
Notes: Data are represented as mean ± SD (n = 3), ***P , 0.001.
Abbreviations: Ad5, adenovirus vectors type 5; APC, cationic PEG derivative; 
PEI,  polyethylenimine;  Ad5/APC,  adenovirus  complexed  with  APC;  Ad5/PEI-2k, 
adenovirus  complexed  with  PEI-2k;  pfu,  plaque  forming  units;  SD,  standard 
deviation.
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assay. As shown in Figure 5, the cytotoxicity of PEI-25k was 
  concentration-dependent in the three cell lines. Ad5 com-
plexed with a low concentration of PEI-25k (1 µg/mL) showed 
little cytotoxicity while the cell viability decreased along with 
the increased concentration of PEI-25k. When the concentra-
tion of PEI-25k rose to 20 µg/mL, the relative cell viability 
decreased to 30.3% ± 3.66% for A549 cells, 22.0% ± 2.62% 
for B16 cells, and 34.8% ± 6.90% for SKOV3 cells. How-
ever, over the range of  designed concentration (1 µg/mL 
∼20 µg/mL), there was no significant difference between 
APC and PEI-2k (P . 0.05), both of which exhibited no 
cytotoxicity to the three cell lines. The result demonstrated 
that the aminated PEG derivative (APC), as well as low MW 
PEI-2k, was a relatively safe polymer to PEI-25k, giving 
APC potential for further study in vitro or in vivo.
In vitro neutralizing assays
To evaluate the ability of Ad5 complexed with APC 
evading anti-Ad5 neutralizing antibody, naked Ad5, 
Ad5/APC, or Ad5/PEI-2k complexes were respectively 
incubated at 37°C for 1 hour with blank serum or anti-
serum isolated from immunized mice or nonimmunized 
mice. The incubated mixtures were then treated with 
A549 cells for transfection assays. As shown in Fig-
ure 6, for the three samples treated with blank serum, 
there were no significant differences between 1:50 dilu-
tion and 1:250 dilution. Wherein, Ad5/APC complex 
achieved gene transduction as efficient as Ad5/PEI-2k, 
significantly more efficient than naked Ad5. The result 
almost matched in vitro transfection assays in Figure 3A. 
When the samples were exposed to antiserum at the dilu-
tion 1:250, the gene transfection efficiency of naked Ad5 
decreased by about 7.1 times, from 1.18 ± 0.014 u/mg to 
0.17 ± 0.02 u/mg, revealing that anti-Ad5 neutralizing 
antibody had been successfully generated by intramus-
cular administration in mice. Comparatively, at the same 
dilution, Ad5/PEI-2k showed a decrease by 5.4 times, 
from 6.44 ± 0.056 u/mg to 1.19 ± 0.016 u/mg, which was 
still a higher transduction than naked Ad5. At the 1:50 
dilution of antiserum, PEI-2k-mediate gene expression 
almost decreased to the same level as naked Ad5, while 
Ad5/APC still exhibited significantly efficient gene 
transfer. Compared with Ad5/APC at the 1:50 dilution 
of antiserum, there was just a 2.4 times decrease from 
5.70 ± 0.13 u/mg to 2.28 ± 0.32 u/mg. Furthermore, 
no significant difference was found for Ad5/APC exposed 
to 1:50 versus 1:250 diluted antiserum. The above results 
revealed that, (1) immunized serum containing NAb 
against Ad5 could inactive naked Ad5 in a titer-related 
way; (2) PEI-2k could partially protect Ad5 evading NAb 
with a low titer relative to Ad5 alone; and, most impor-
tantly, (3) APC was significantly better at allowing Ad5 
to escape from NAb than PEI-2k, which may be due to the 
effect of PEG being present on the APC polymer.
Figure 4 Transmission electron microscopy images of the naked adenovirus (A) and adenovirus complexed with APC (B).
Note: Arrow bar = 100 nm.
Abbreviation: APC, cationic PEG derivative.
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Figure 5 Relative viability of (A) A549, (B) B16, and (C) SKOV3 cells treated with Ad5 
(1.25 × 106 pfu/well) complexed with a serial concentration of APC, PEI-25k, and PEI-2k 
over the range from 1 µg/mL to 20 µg/mL. Each sample has five repeated wells.
Notes:  Data  are  represented  as  mean  ±  SD  (n  =  5),  *P  ,  0.05,  **P  ,  0.01, 
***P , 0.001.
Abbreviations:  Ad5,  adenovirus  vectors  type  5;  pfu,  plaque  forming  units; 
PEI, polyethylenimine; APC, cationic PEG derivative; SD, standard devation.
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Discussion
To construct a safe and efficient Adv-based vector system 
which is robust in the presence of NAb and permits repeated 
administration in clinical trials, a number of polymers have 
been extensively investigated to incorporate onto the surface 
of adenovirus. Thus, a shielded vector was formed to prevent 
Adv from interaction with proteins or cells in blood, induce 
low immune response, and facilitate Adv evading Nab.39–42 In 
our study, the cationic PEG derivative (APC), a linear PEG 
with one side blocked by amines, was designed to modify the 
surface protein of Ad5 by physical adsorption. The complex 
(Ad5/APC) with PEG extending outside achieved a satisfi-
able protection of Adv from NAb as well as highly enhanced 
gene expression efficiency.
Prior to the synthesis of APC, the size of PEG and the 
number of amine pendants had been taken into serious con-
sideration. In general, 3∼5k MW of PEG were frequently 
used to form a compact coating. But recently, some reports 
revealed that the size and density of PEG anchored on to 
the surface protein of adenovirus played a crucial part in 
the biodistribution in vivo.25,43,44 Large size of PEG (20 kd) 
not small size (3−5 kd) remarkably facilitated detargeting 
from liver thus relatively reduced hepatotoxicity and made 
systemic administration of adenovirus possible as well as 
allowing evasion from NAb. Therefore, APC   (approximately 
20 kd) with linear PEG (approximately 13 kd) was syn-
thesized in the current study. Meanwhile, the number of 
primary amines mounting on one side of APC, which was 
closely related to the density of APC anchored onto Ad5, 
was evaluated as 36 according to GPC and elementary 
analysis. Branched PEI-2k contains a total of about 50 
amines, of which primary amines account for 25% and 
secondary amines 50%. Comparatively, APC may bear more 
positive charge than PEI-2k. Additionally, we had tried to 
reduce the number of amines by a third via a lower AGE 
mole ratio, but weaker protection ability from NAb was 
obtained (data not shown). The optimal number of amines 
requires further study.
In the past, cationic polymers have been explored to carry 
plasmid or viruses for gene delivery, with achievement of 
improved gene transduction. One explanation for the enhanced 
effect was that positively charged complexes (Adv/polymers) 
facilitated interaction with negatively charged cells. At a start-
ing point to select a control to APC in our study, PEI-600, PEI-
2k, and PEI-25k were respectively complexed with Ad5 at the 
optimal ratio then applied to A549 cells. We found there was 
no significant difference between PEI-25k and naked Ad5 for 
Adv-based gene   expression. Interestingly, PEI-2k was far supe-
rior to PEI-600 or PEI-25k, and had 10 times enhanced gene 
expression than naked Ad5 (data not shown). Commercially 
branched PEI-25k as one of the most efficient polymers in gene 
transduction, was usually used as a benchmark to other bio-
materials especially newly synthesized polymers for carrying 
gene delivery.45,46 Similarly, authors have shown that PEI-25k   
exhibited somewhat lower gene expression of Adv than naked 
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Adv in A549 cells and C2C12 cells.45 A recent report indicated 
that PEI-25k significantly enhanced Adv uptake but had no 
effect on transgenic expression, compared to naked Adv.47 
Normally, Adv-mediated gene delivery begins with binding 
and internalization into cells. During endocytosis, fibers are 
detached. Afterwards, hexons, pentons, and other structural 
proteins are dissociated, resulting in Adv escaping from endo-
some into cytosol and subsequent import to nucleus via inter-
action with cytoplasmic dynein.22,48 Each step may influence a 
successful delivery. Since PEI-25k   facilitates Adv internaliza-
tion but not transgenic expression, this suggests that PEI-25k 
bears more positive charge, affording a strong electrostatic 
force for Adv/PEI-25k complex and a difficult release for Adv 
from the polymer. Comparatively, PEI-2k may mediate a better 
Adv gene delivery among the PEI polymers.
In our study, PEI-2k showed 10 times more efficient gene 
expression than naked Adv in A549 cells. To the best of our 
knowledge, the enhanced transduction of Adv mediated by 
PEI-2k has not been reported previously. In our study, Ad5/
APC complex enhanced Ad5-mediated gene transfer to the 
same extent as PEI-2k in CAR-positive cells (A549) or 
CAR-negative cells (B16), and interestingly, significantly 
more greatly than PEI-2k in CAR-deficient cells (SKOV3). 
The significant difference of gene expression between Ad5/
PEI-2k and Ad5/APC in SKOV3 needs further exploration. 
The observed enhanced gene expression by APC was 
meaningful: (1) It makes lower doses of Adv available 
− higher doses of Adv induce a severe immunoresponse 
and hepatotoxicity.49 (2) Adv infect cells mainly via CAR-
dependent endocytosis,50,51 leaving a limit to be internalized 
by CAR-poor tumor cells. Polymer coatings gifted Adv with 
CAR-ablated infection ability for nonspecific cell uptake.52 
(3) A ligand can be added to retarget for in vivo study and 
prevent unwanted binding of Ad5 to human erythrocytes 
which were found to be present in CAR.53
The physical property of Ad5 alone or Ad5/APC complex 
was characterized by measurements of particle size and zeta 
potential. Ad5/PEI-2k complex had an average diameter of 
1382 ± 79.9 nm. The result was in agreement with previous 
reports that cationic polymers without exception induced 
severe aggregation of viral vectors.27 The aggregation enabled 
a greater contact of adenovirus to cell monolayer, which was 
another mechanism proposed for enhanced gene transduction 
by cationic polymers.52,54 But complexes up to 1 micrometer 
in size may afford poor permeability into tumor vessels where 
the maximum diameter size of 400∼600 nm was required.55 
The unstable complex may potentially interact with negatively 
charged protein or cells, inducing immediate cytotoxicity. 
While APC makes a stable hybrid vector, 130.2 ± 0.60 nm is 
a slightly increased diameter than adenovirus alone. Ad5/APC 
complexes with such a size may benefit from enhanced per-
meability and retention effect when applied in vivo for cancer 
treatment.56 The TEM image of Ad5/APC supported that Ad5/
APC complexes have been formed in shell core structure.
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Figure 6 Neutralizing assays in A549 cells treated with Ad5 alone (1.25 × 107 pfu), Ad5/PEI-2k or Ad5/APC at the optimal ratio. Before transfection, a neutralizing effect was 
processed by incubation of naked Ad5 or freshly prepared complexes (Ad5/PEI-2k or Ad5/APC) and complement-inactivated blank serum or antiserum which respectively 
isolated from nonimmunized or immunized C57BL/6 N mice at 37°C for 1 hour. The following processes were performed as described in in vitro transfection assays.
Notes: Data are represented as mean ± SD (n = 3), ***P , 0.001.
Abbreviations: Ad5, adenovirus vectors type 5; PEI, polyethylenimine; APC, cationic PEG derivative; pfu, plaque forming units; Ad5/PEI-2k, adenovirus complexed with 
PEI-2k; Ad5/APC, adenovirus complexed with APC; SD, standard deviation.
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Furthermore, cytotoxicity is the bottleneck for cationic 
polymers such as PEI to be utilized in clinics. The polymer 
cytotoxicity is closely related to factors such as MW, con-
centration of free cationic polymers, ionic strength, and the 
processes after entry into cells.39,57 For plasmids, gene expres-
sion efficiency is in proportion to polymeric size. High gene 
expression efficiency needs a large size but is accompanied 
by severe cytotoxicity. Furthermore, in vivo studies require 
highly increased doses of complex, thus the release of nonbio-
degradable polymer from the complex after entry into cells is a 
nondesirable side effect. To reduce cytotoxicity, biodegradable 
biomaterials have been widely investigated. Another effective 
strategy is the introduction of PEG into cationic polymers. As 
reported, PEG can prevent cationic complexes from interac-
tion with other proteins, thus stabilizing the complex and 
reducing cytotoxicity.58,59 For example, it was demonstrated 
that PLL (24 kd) showed cytotoxicity to KB cells from 1 
µg/mL, but PLL (24 kd) with a PEG grafting ratio of 8.4% 
(PLL-g-PEG) showed little cytotoxicity over the range of 1 
µg/mL to 10 µg/mL.59 The low cytotoxity of APC in our study 
warrants further investigation of the complex.
Although APC enabled a stable, low toxic Ad5-mediated 
system with high gene transduction efficiency, Ad5-mediated 
gene therapy has also been hindered by the neutralization 
of NAb towards Adv, making readministration problematic. 
Shielding antigen epitope of Adv and avoidance of recogni-
tion by NAb are anticipated. Therefore, it is key to develop 
a stable and robust Adv-shielded vector before endocytosis 
into cells. In the present study, APC-based protection abil-
ity of Ad5 from NAb was evaluated. The results indicated 
that commercial PEI-2k offered weak protection of Ad5 
from NAb. But the Ad5/APC complex showed relatively 
good resistance to NAb. This superior protection effect was 
mainly contributed by the PEG segments present on APC. 
The unstable Ad5/PEI-2k complex may be more susceptible 
to NAb or other negatively charged proteins in serum than the 
Ad5/APC complex. In addition, polymer coating by physical 
adsorption permitted a systemic administration by reducing 
hepatic uptake and extending blood half-life.41,60 Therefore, 
APC may be a potential Adv-carrier for gene therapy.
Taken together, we present a novel polymer-coated Adv 
delivery system, which is simple, stable, has low toxicity, and 
is highly efficient in transgenic expression. More importantly, 
this system offered good protection of Adv from NAb in 
vitro. This Adv delivery system is based on a newly designed 
cationic PEG derivative. If necessary, PEG length and amines 
pendants or positive charge present on the copolymer can 
be easily optimized by adjusting the molar ratio among 
Boc-aminoethanol, EO, and AGE. Meanwhile, the amines of 
the copolymer afford many conjunctive sites for the conjuga-
tion of ligands or active proteins, thus it is more susceptible to 
reconstruct a specifically desired   copolymer. In future studies, 
we will investigate in vivo delivery of APC under the establish-
ment of a pre-existing immunized animal model.
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